Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors
JNJ(NYSE:JNJ) NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. “We are pleased to welcome John to our Company’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “He is a proven leader of a large multinational organization who possesses a strong understanding of global
Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum
JNJ(NYSE:JNJ) NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fireside Chat at 1:10 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available app
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
JNJ(NYSE:JNJ) NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & J
Haut.AI Collaborates with Neutrogena® on The Refresh of Iconic Neutrogena Skin360® with Advanced AI-Driven Skin Analysis Technology
JNJ(NYSE:JNJ) NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Haut.AI is excited to announce its collaboration with Neutrogena® on the official refresh of the iconic Skin360™ experience, now supercharged by Haut.AI's cutting-edge AI skin analysis technology. This next-generation refresh delivers...
New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump
JNJ(NYSE:JNJ) MADRID, Aug. 31, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) – Late breaking clinical science data, presented at the European Society of Cardiology (ESC) Congress today and simultaneously published in the New England Journal of Medicine (NEJM), finds at up to 10 years, when...
AMDR Applauds Federal Court Decision to Bar Johnson & Johnson’s Biosense Webster Unit from Further Violation of Anti-Trust Laws in a Win for Hospitals, Patients, and the Environment
JNJWASHINGTON--(BUSINESS WIRE)--The Association of Medical Device Reprocessors (AMDR) announced that Judge James Selna of the U.S. District Court for the Central District of California has issued a permanent injunction against Johnson & Johnson’s (NYSE: JNJ) Biosense Webster (BSW) medical device unit for unlawful, anti-competitive conduct. The ruling prohibits BSW from blocking hospitals’ access to safe, lower-cost, FDA-regulated reprocessed cardiac catheters. The decision follows a jury verdi
Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit
JNJBOSTON--(BUSINESS WIRE)--A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson’s (NYSE:JNJ) talcum powder products. The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company’s asbestos-contaminated talcum powder products caused Paluzzi’s terminal cancer. During the trial, the Dean Omar Branham Shirley legal team, which represent
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
JNJResults from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs MILAN,...
Johnson & Johnson Announces Bleximenib, Investigational Selective Menin Inhibitor, Shows Potential As Combination Therapy For Treatment Of Relapsed Or Refractory AML And Newly Diagnosed, Intensive Chemo-Ineligible AML
JNJJohnson & Johnson's TREMFYA Reduces Joint Damage And Improves Psoriatic Arthritis Symptoms In Phase 3b APEX Study, With Over 40% Achieving ACR50 And Majority Showing No Radiographic Progression At 24 Weeks
JNJJohnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
JNJNEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We are thrilled to have Daniel join Johnson & Johnson’s Board of Directors,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel’s unique perspective and wealth of experience wi
12 Analysts Have This To Say About Johnson & Johnson
JNJRBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target
JNJJohnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation
JNJJohnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple myeloma patients.
Johnson & Johnson Says New Long-Term CARTITUDE-1 Data Show One-Third Of Patients Treated With CARVYKTI Remain Progression-Free
JNJJohnson & Johnson Announces Data From Two Studies Highlighting That DARZALEX FASPRO-Based Quadruplet Regimen Demonstrated Deep And Sustained MRD Negativity Rates, And Improved Long-Term PFS In NDMM Patients
JNJJohnson & Johnson Announces Initial Phase 1 Results Of JNJ-79635322, Investigational TsAb In Patients With Relapsed Or Refractory Multiple Myeloma
JNJJohnson & Johnson's AKEEGA Combo Shows Nearly 50% Reduction In Disease Progression For BRCA-Altered Prostate Cancer In Phase 3 AMPLITUDE Study
JNJP/E Ratio Insights for Johnson & Johnson
JNJReported Earlier, J&J's DARZALEX FASPRO Wins US FDA Oncologic Drugs Advisory Committee Backing For Early Intervention In HR-SMM, Potentially Preventing Disease Progression
JNJMarket Whales and Their Recent Bets on JNJ Options
JNJReported Sunday, Innovative Health Secures Landmark $147M Verdict Against J&J Unit Over Anti-Competitive Tactics Targeting Reprocessed Medical Devices
JNJ'MHRA Approves Guselkumab For Crohn's Disease And Ulcerative Colitis'
JNJ13 Analysts Have This To Say About Johnson & Johnson
JNJPeering Into Johnson & Johnson's Recent Short Interest
JNJLeerink Partners Downgrades Johnson & Johnson to Market Perform, Lowers Price Target to $153
JNJMark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company…Ask Your PBM For A List Of Claims'
JNJMark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
JNJProtagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.
Oric Pharmaceuticals Announces Clinical Trial Collaboration And Supply Agreement With Johnson & Johnson To Evaluate ORIC-114 In Combination With Subcutaneous Amivantamab For The First-Line Treatment Of NSCLC Patients With EGFR Exon 20 Insertion Mutations
JNJJohnson & Johnson Says Data From QUASAR LTE Study Demonstrate Patients Treated With TREMFYA Sustained Clinical And Endoscopic Efficacy At Week 92
JNJJohnson & Johnson Announces New Data From TREMFYA Phase 3 QUASAR LTE Study In Adults With Moderately-To-Severely Active Ulcerative Colitis
JNJJohnson & Johnson Announces New Data From Phase 3 ASTRO Study Evaluating TREMFYA Subcutaneous Induction Therapy In Adults With Ulcerative Colitis
JNJJohnson & Johnson Receives FDA Approval For IMAAVY, A New FcRn Blocker Offering Long-Lasting Disease Control In The Broadest Population Of People Living With Generalized Myasthenia Gravis
JNJPlaintiff Sues Eli Lilly, Johnson & Johnson Over Alleged Breast Cancer Risk Linked To Antipsychotic Medications
JNJA lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa.
Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival
JNJRoche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
JNJRoche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states.
Johnson & Johnson Says First Results From Cohort 4 Of Phase 2B Sunrise-1 Study Show Potential Of TAR-200 Monotherapy In Patients With Papillary-only, High-risk Non-muscle Invasive Bladder Cancer
JNJJohnson & Johnson Says TAR-200 Monotherapy Shows Highest Complete Response With Sustained Benefits In 12-month Data From Phase 2B SunRISe-1 Study (Cohort 2)
JNJBarclays Maintains Equal-Weight on Johnson & Johnson, Lowers Price Target to $165
JNJRaymond James Maintains Outperform on Johnson & Johnson, Raises Price Target to $164
JNJHow Is The Market Feeling About Johnson & Johnson?
JNJMorgan Stanley Maintains Equal-Weight on Johnson & Johnson, Raises Price Target to $169
JNJRBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $181 Price Target
JNJJohnson & Johnson's Q1 Results, FY Guidance Highlight The 'Power Of The Pharma Portfolio'
JNJJohnson & Johnson (JNJ) reported upbeat Q1 results amid an exciting earnings season, with analysts noting impressive sales and guidance from the pharma giant.
Johnson & Johnson Q1 Earnings: Strong Cancer Drug Sales, Boosts Quarterly Dividend, Anticipates Negative Currency Impact For 2025 Profit
JNJJohnson & Johnson raised its 2025 sales outlook and dividend, while Q1 results topped expectations driven by strong cancer drug performance.
Johnson & Johnson Declared 4.8% Increase In The Quarterly Dividend, From $1.24 Per Share To $1.30, Payable On June 10 To Shareholders Of Record At The Close Of Business On May 27
JNJJohnson & Johnson Expects 2025 Adjusted EPS Of $10.50-$10.70 Versus Prior Guidance Of $10.75–$10.95 And Consensus Of $10.46
JNJJohnson & Johnson Expects 2025 Sales Of $91B-$91.8B Versus Prior Guidance Of $90.9B–$91.7B And Consensus Of $90.62B
JNJJohnson & Johnson Q1 2025 Adj EPS $2.77 Beats $2.60 Estimate, Sales $21.89B Beat $21.58B Estimate
JNJJohnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
JNJ